Intended for healthcare professionals

Letters Screening for hepatitis C

NICE’s recommendation on sofosbuvir for hepatitis C

BMJ 2015; 350 doi: (Published 24 February 2015) Cite this as: BMJ 2015;350:h637
  1. Padmanabhan Badrinath, consultant in public health medicine and associate clinical lecturer, University of Cambridge1
  1. 1Suffolk Public Health, Suffolk County Council, Endeavour House, Ipswich IP1 2BX, UK
  1. badrishanthi{at}

Koretz and colleagues point out that new hepatitis C drugs need to be evaluated by long term follow-up of clinical outcomes and not just surrogate markers.1 However, the National Institute of Health and Care excellence (NICE) based its recommendation in its final appraisal determination solely on “virological response.”2 Regarding side effects, the authors state “in a …

View Full Text

Log in

Log in through your institution


* For online subscription